menu
    • menu
    [{"orgOrder":0,"company":"Trueline Therapeutics","sponsor":"Broad Institute of Harvard","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TTX-810","moa":"MCL1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Trueline Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Trueline Therapeutics \/ Broad Institute of Harvard","highestDevelopmentStatusID":"5","companyTruncated":"Trueline Therapeutics \/ Broad Institute of Harvard"}]

    Find Clinical Drug Pipeline Developments & Deals by Trueline Therapeutics

    Menu

    Trueline Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Trueline Therapeutics

                            U.S.A arrow
                            Peptide Therapy Summit
                            Not Confirmed

                            Trueline Therapeutics

                            U.S.A arrow
                            Peptide Therapy Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TTX-810

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Broad Institute of Harvard

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Trueline Therapeutics Announces Completion of IND-Enabling Studies for MCL1 Inhibitor TTX-810

                            Details : TTX-810 is an IND-enabling candidate, a MCL1 inhibitor, a highly potent and selective macrocyclic compound to treat patients with solid tumor or hematological cancers.

                            Product Name : TTX-810

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 16, 2023

                            Lead Product(s) : TTX-810

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Broad Institute of Harvard

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth